First patient treated in the U.S. Initial enrollment planned for the U.S., Japan, and Taiwan, with further expansion to additional countries and regions SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision,...
Read More Details
Finally We wish PressBee provided you with enough information of ( Rakuten Medical Announces Initiation of Global Phase 3 Trial of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for First-Line Recurrent Head and Neck Cancer )
Also on site :
- What we know about aid queue killings in Gaza
- US condemns multi-nation sanctions on far-right Israeli ministers
- Mike Huckabee, U.S. Ambassador to Israel, Questions Palestinian State Policy